Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.
PPMI is taking place at clinical sites in the United States, Europe, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which will be available to the scientific community to conduct field-changing research.
PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
Learn more about Who We Are.
PPMI’s Biospecimen Review Committee (BRC) convenes every other month to review requests to use available specimens being housed at Corriell, which serves as the PPMI biorepository. To date, 23 requests have been made for use of the biospecimens. Two of those requests have been accepted and fulfilled.
PPMI has launched a new study arm to enroll and follow a prodromal PD cohort with the goal of providing researchers with the opportunity to examine biomarker progression prior to the onset of motor symptoms. This new cohort seeks to enroll subjects without Parkinson’s disease who have at least one of the following characteristics: hyposmia, REM sleep behavior disorder, LRRK2 genetic mutation.
PPMI has now finished recruiting the 400 de novo PD and 200 control subjects the study originally set out to identify. This is an important milestone for the study and for those wishing to take advantage of its growing dataset. Already, more than 54,000 downloads have been made from scientists in 37 countries across the globe. In the coming months, the PPMI Steering Committee plans to present at various meetings and publish a paper that will reference the baseline data as a description of the 600+ participants enrolled in PPMI.
See the actual numbers of samples of CSF, urine, RNA, serum and plasma that have been collected in PPMI to date.
This March, the Parkinson’s Progression Markers Initiative (PPMI) will launch a new study arm to enroll and follow a prodromal Parkinson’s disease (PD) cohort. Defining a pre-diagnostic or prodromal phase for PD presents both an immediate challenge – how to reliably identify individuals during this prodromal period at high risk to phenoconvert to PD – [...]
